Novartis 2Q Revenues: $14.5 billion (+1%) 2Q Earnings: $2.5 billion (-5%) YTD Revenues: $28.5 billion (+2%) YTD Earnings: $5.0 billion (+1%) Comments: Pharmaceuticals sales were $8.1 billion in the quarter, down 2%. Gilenya, Afinitor, Tasigna, Galvus, Xolair, the Q Family and Jakavi contributed $4.5 billion or 31% of group sales, up 13%. Generics impacted sales by approximately $0.8 billion due to Diovan and Zometa, but a U.S. generic for Diovan has yet to be approved by FDA, forestalling a...